Metraipolis › archive › dc_3b22fa694d60
Accelerated approval (FDA) — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Accelerated_approval_(FDA)
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-07T10:01:31.744Z
- SHA-256 of the archived text
f30724a36a219837f7b44f61304aa5c2e2b9a10b5f595af1fc8d8a8bad4f41d5- Stable URL of this page
https://metraipolis.com/documento/dc_3b22fa694d60
How to cite
Accelerated approval (FDA) — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Accelerated_approval_(FDA) (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_3b22fa694d60 (Metraipolis archive dc_3b22fa694d60, sha256 f30724a36a219837f7b44f61304aa5c2e2b9a10b5f595af1fc8d8a8bad4f41d5)
BibTeX
@misc{dc3b22fa694d60,
title = {Accelerated approval (FDA) — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Accelerated_approval_(FDA)},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_3b22fa694d60; sha256 f30724a36a219837f7b44f61304aa5c2e2b9a10b5f595af1fc8d8a8bad4f41d5},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Accelerated_approval_(FDA). Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The United States Food and Drug Administration (FDA) initiated the FDA Accelerated Approval Program in 1992 to allow faster approval of drugs for serious conditions that fill an unmet medical need. The faster approval relies on use of surrogate endpoints. Drug approval typically requires clinical trials with endpoints that demonstrate a clinical benefit, such as increased survival for cancer patients. Drugs with accelerated approval can initially be tested in clinical trials that use a surrogate endpoint, or something that is thought to predict clinical benefit. Surrogate endpoints typically require less time, and in the case of a cancer patient, it is much faster to measure a reduction in tumor size, for example, than overall patient survival. Drugs approved under the FDA Accelerated Approval Program still need to be tested in clinical trials using endpoints that demonstrate clinical benefit, and those trials are known as phase 4 confirmatory trials. If the drug later proves unable to demonstrate clinical benefit to patients, the FDA may withdraw approval. A study published in 2023, following a similar study focused on oncology in 2022, suggested that the Accelerated Approval Program was having the intended impact of shortening the timeline to either traditional approval or withdrawal of applications in cases where confirmatory trials had begun before the start of the Accelerated Approval process; further, there appeared to be no impact on the ratio of approval to withdrawal whether accelerated or traditional pathway was used. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Accelerated approval (FDA)» — https://en.wikipedia.org/wiki/Accelerated_approval_(FDA) Wikidata Q17005771: «US program for faster approval of drugs» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q17005771 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Accelerated_approval_(FDA)?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1379642180, consultata il 2026-11-07T09:55:29.252Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 76a4eb6a5ae432f05e1d9c0c53c0a07bb93b2654ceb95d704fa04c22c24a8898